Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients
[en] ACE inhibition protects kidney function, but ACE insertion/ deletion (LID) polymorphism affects renal prognosis in type 1 diabetic patients'. ACE genotype may influence the renal benefits of ACE inhibition. We studied the impact of ACE 1/D polymorphism on the renal hemodynamic changes induced by ACE inhibition in type 1 diabetes. We studied renal hemodynamics (glomerular filtration rate [GFR], effective renal plasma flow [ERPF], filtration fraction [GFR/ERPF], mean arterial pressure [MAP], and total renal resistances [MAP/ ERPF]) repeatedly during normoglycemia, and then hyperglycemia in 12 normotensive, normoalbuminuric type 1 diabetes and the 11 genotype (associated with nephrorotection) versus 22 age- and sex-matched subjects with the ACE D allele after three randomly allocated 2- to 6-week periods on placebo, 1.25 mg/day ramipril, and 5.mg/day ramipril in A double-blind, cross-over study. During normoglycemia, the hemodynamic changes induced by ramipril were similar in both genotypes. During hyperglycemia, the changes induced by ramipril were accentuated in the 11 genotype group and attenuated dose dependently in the D allele group (treatment-genotype interaction P values for ERPF, 0.018; MAP 0.018; and total renal resistances, 0.0.55). These results provide a basis to. different renal responses to ACE inbibition according to ACE genotype in type 1 diabetes.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Weekers, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Bouhanick, B.
Hadjadj, S.
Gallois, Y.
Roussel, R.
Pean, F.
Ankotche, A.
Chatellier, G.
Alhenc-Gelas, F.
Lefebvre, P. J.
Marre, M.
Language :
English
Title :
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients
Publication date :
October 2005
Journal title :
Diabetes
ISSN :
0012-1797
eISSN :
1939-327X
Publisher :
Amer Diabetes Assoc, Alexandria, U.S. Virgin Islands
Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br Med J 313:779-784, 1996
Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375-380, 1982
Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Tripoddo NC: Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 233:F366-F372, 1977
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion deletion polymorphism in angiotensin I conversion enzyme accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
Marre M, Chatellier G, Leblanc H, Guyenne TT, Menard J, Passa P: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 297:1092-1095, 1988
Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134:370-379, 2001
Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B: Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54:1238-1244, 2005
Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 12:541-549, 2001
Rudberg S, Rasmussen LM, Bangstad H-J, Osterby R: Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 23:544-548, 2000
Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. Br Med J 313:591-594, 1996
Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong L-A, Fuller JH, EUCLID Study Group: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. Diabetes 47:1507-1511, 1998
Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410-415, 1981
Marre M, Bouhanick B, Berrut G, Gallois Y, Le Jeune JJ, Chatellier G, Menard J, Alhenc-Gelas F: Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension 33:775-780, 1999
Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group, J Clin Invest 99:1585-1595, 1997
Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
Tarnow L, Gluud C, Parving HH: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13:1125-1130, 1998
Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud P: Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 18 (Suppl. 2):S165-S168, 1991
O'Hare P, Bilous R, Mitchell T, O'Callaghan CJ, Viberti GC: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 23:1823-1829, 2000
Thuillez C, Richer C, Giudicelli JF: Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers. Am J Cardiol 59:38D-44D, 1987
White NH, Skor D, Santiago JV: Practical closed-loop insulin delivery: a system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics. Ann Intern Med 97:210-213, 1982
Visscher CA, de Zeeuw D, de Jong PE, Sluiter WJ, Huisman RM: Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. Kidney Int 48:1617-1623, 1995
Danilov S, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, Tarnow L, Alhenc-Gelas F: Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens 14:719-727, 1996
Menard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R: Direct immunometric assay of active renin in human plasma. J Hypertens 3 (Suppl.):S275-S278, 1985
Pham-Huu-Trung MT, Corvol P: A direct determination of plasma aldosterone. Steroids 24:587-588, 1974
Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P: Laser immunonephelometry for routine quantification of urinary albumin excretion. Clin Chem 33:209-213, 1987
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252-1256, 1998
Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardio-vascular events in high-risk patients. N Engl J Med 342:145-153, 2000
Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br Med J 328: 495, 2004
Miller JA, Scholey JW, Thai K, Pel YP: Angiotensin converting enzyme gene polymorphism and renal hemodynamic function in early diabetes. Kidney Int 51:119-124, 1997
Luik PT, Hoogenberg K, Kerstens MN, Beusekamp BJ, De Jong PE, Dullaart RP, Navis GJ: The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric type 1 diabetes mellitus. Diabetologia 46:1131-1139, 2003
Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J: Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942, 1995
Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK: Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 36:122-126, 2000
Miller JA: Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10:1778-1785, 1999
Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
Ito S, Arima S, Ren YL, Juncos LA, Carretero OA: Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91:2012-2019, 1993
Pieper GM: Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 31:1047-1060, 1998
Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia Inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348, 2001
O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100:678-684, 1997
Chobanian AV, Hope S, Brecher P: Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension 25:1306-1310, 1995
Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW: Nephropathy in diabetes. Diabetes Care 27 (Suppl. 1):S79-S83, 2004
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720, 1995
Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26:1501-1506, 2003